US Patent 8101743 Modulation of transthyretin expression
Patent 8101743 was granted and assigned to Ionis Pharmaceuticals on January, 2012 by the United States Patent and Trademark Office.
All edits
Edits on 27 Dec, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 28 Nov, 2023
Golden AI
Edits made to:
Article (+397 characters)
Article
Patent abstract
Compounds, compositions and methods are provided for modulating the expression of transthyretin. The compositions comprise oligonucleotides, targeted to nucleic acid encoding transthyretin. Methods of using these compounds for modulation of transthyretin expression and for diagnosis and treatment of diseases and conditions associated with expression of transthyretin are provided.
Edits on 20 Sep, 2023
Golden AI
Edits made to:
Infobox (+2 properties)
Infobox
Patent Inventor Names
Ravi Jain0
Vickie L. Brown-Driver0
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08101743 Modulation of transthyretin expression US Patent 8101743 Modulation of transthyretin expression
Infobox
Patent Number
081017430
Patent Number
81017430
Edits on 24 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
081017430
Date of Patent
January 24, 2012
0Patent Application Number
122737310
Date Filed
November 19, 2008
0Patent Primary Examiner
Edits on 14 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08101743 Modulation of transthyretin expression
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08101743
Date of patent
January 24, 2012
Patent application number
12273731
Date Filed
November 19, 2008
Patent primary examiner
Find more entities like US Patent 8101743 Modulation of transthyretin expression
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.